# Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma

> **NCT06903273** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cheng-Kung University Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Cholangiocarcinoma
- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06903273
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-03-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903273, "Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT06903273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*